Search

Your search keyword '"De Bree, Remco"' showing total 20 results
Start Over Author "De Bree, Remco" Journal european journal of nuclear medicine and molecular imaging
20 results on '"De Bree, Remco"'

10. Within-patient comparison between [68Ga]Ga-tilmanocept PET/CT lymphoscintigraphy and [99mTc]Tc-tilmanocept lymphoscintigraphy for sentinel lymph node detection in oral cancer: a pilot study

Author

Mahieu, Rutger, primary, Donders, Dominique N. V., additional, Krijger, Gerard C., additional, Ververs, F. F. Tessa, additional, de Roos, Remmert, additional, Bemelmans, John L. M. M., additional, van Rooij, Rob, additional, de Bree, Remco, additional, and de Keizer, Bart, additional

Published
2021
Full Text
View/download PDF

12. Joint practice guidelines for radionuclide lymphoscintigraphy for sentinel node localization in oral/oropharyngeal squamous cell carcinoma

Author

Alkureishi, Lee W. T., Burak, Zeynep, Alvarez, Julio A., Ballinger, James, Bilde, Anders, Britten, Alan J., Calabrese, Luca, Chiesa, Carlo, Chiti, Arturo, de Bree, Remco, Gray, Harry W., Hunter, Keith, Kovacs, Adorjan F., Lassmann, Michael, Leemans, C. Rene, Mamelle, Gerard, McGurk, Mark, Mortensen, Jann, Poli, Tito, Shoaib, Taimur, Sloan, Philip, Sorensen, Jens A., Stoeckli, Sandro J., Thomsen, Jorn B., Trifiro, Giusepe, Werner, Jochen, Ross, Gary L., and The European Association of Nuclear Medicine (EANM) Oncology Committee and European Sentinel Node Biopsy Trial (SENT) Committee

Published
2009
Full Text
View/download PDF

19. The impact of tumour volume and other characteristics on uptake of radiolabelled monoclonal antibodies in tumour tissue of head and neck cancer patients

Author

de Bree, Remco, primary, Kuik, Dirk J., additional, Quak, Jasper J., additional, Roos, Jan C., additional, van den Brekel, Michiel W. M., additional, Castelijns, Jonas A., additional, van Wagtendonk, Frank W., additional, Greuter, Henri, additional, Snow, Gordon B., additional, and van Dongen, Guus A. M. S., additional

Published
1998
Full Text
View/download PDF

20. Quantification of 18F-fluorodeoxyglucose uptake to detect residual nodal disease in locally advanced head and neck squamous cell carcinoma after chemoradiotherapy: results from the ECLYPS study.

Author

Helsen N, Van den Wyngaert T, Carp L, De Bree R, VanderVeken OM, De Geeter F, Maes A, Cambier JP, Spaepen K, Martens M, Hakim S, Beels L, Hoekstra OS, Van den Weyngaert D, Stroobants S, Van Laer C, Specenier P, Maes A, Debruyne P, Hutsebaut I, Van Dinter J, Homans F, Goethals L, Lenssen O, and Deben K

Subjects
Chemoradiotherapy, Fluorodeoxyglucose F18, Humans, Neoplasm Recurrence, Local, Positron Emission Tomography Computed Tomography, Positron-Emission Tomography, Prospective Studies, Squamous Cell Carcinoma of Head and Neck diagnostic imaging, Squamous Cell Carcinoma of Head and Neck therapy, Carcinoma, Squamous Cell diagnostic imaging, Carcinoma, Squamous Cell therapy, Head and Neck Neoplasms diagnostic imaging, Head and Neck Neoplasms therapy
Abstract

Background: The Hopkins criteria were introduced for nodal response evaluation after therapy in head and neck cancer, but its superiority over quantification is not yet confirmed., Methods: SUV body weight thresholds and lesion-to-background ratios were explored in a prospective multicenter study of standardized FDG-PET/CT 12 weeks after CRT in newly diagnosed locally advanced head and neck squamous cell carcinoma (LAHNSCC) patients (ECLYPS). Reference standard was histology, negative FDG-PET/CT at 12 months after treatment or ≥ 2 years of negative follow-up. Area under the receiver operator characteristics curves (AUROC) were estimated and obtained thresholds were validated in an independent cohort of HNSCC patients (n = 127)., Results: In ECLYPS, 124 patients were available for quantification. With a median follow-up of 20.4 months, 23 (18.5%) nodal neck recurrences were observed. A SUV 70 threshold of 2.2 (AUROC = 0.89; sensitivity = 79.7%; specificity = 80.8%) was identified as optimal metric to identify nodal recurrence within 1 year after therapy. For lesion-to-background ratios, an SUV 50 /SUV liver threshold of 0.96 (AUROC = 0.89; sensitivity = 79.7%; specificity = 82.8%) had the best performance. Compared with Hopkins criteria (AUROC = 0.81), SUV 70 and SUV 50 /SUV liver provided a borderline significant (p = 0.040 and p = 0.094, respectively) improvement. Validation of thresholds yielded similar AUROC values (SUV 70  = 0.93, SUV 50 /SUV liver  = 0.95), and were comparable to the Hopkins score (AUROC = 0.91; not statistically significant)., Conclusion: FDG quantification detects nodal relapse in LAHNSCC patients. When using EARL standardized PET acquisitions and reconstruction, absolute SUV metrics (SUV 70 threshold 2.2) prove robust, yet ratios (SUV 50 /SUV liver , threshold 0.96) may be more useful in routine clinical care. In this setting, the diagnostic value of quantification is comparable to the Hopkins criteria., Trial Registration: US National Library for Medicine, NCT01179360. Registered 11 August 2010, https://clinicaltrials.gov/ct2/show/NCT01179360.

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results